Phthalazinone derivatives
Compounds of the formula (I): wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NR X or CR X R Y ; if X═NR X then n is 1 or 2 and if X═CR X R Y then n is 1; R X is selected from the group consisting of H, optionally substituted C 1-20 alkyl, C 5-20 aryl, C 3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; R Y is selected from H, hydroxy, amino; or R X and R Y may together form a spiro-C 3-7 cycloalkyl or heterocyclyl group; R C1 and R C2 are both hydrogen, or when X is CR X R Y , R C1 , R C2 , R X and R Y , together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R 1 is selected from H and halo.
1. A method of treatment for breast or ovarian cancer deficient in a HR dependent DNA DSB repair pathway comprising administering to a subject a therapeutically effective amount of a compound of formula (Ib):
or an isomer or salt thereof, or a mixture of any thereof, wherein:
A and B together represent a fused aromatic ring, optionally substituted with one or more substituent groups selected from halo, nitro, hydroxyl, ether, thiol, thioether, amino, C 1-7 alkyl, C 5-20 aryl and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur;
R X is selected from H, C 1-20 alkyl, C 5-20 aryl, amido, thioamido, ester, acyl, sulfonyl groups and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur, wherein the acyl, C 1-20 alkyl, C 5-20 aryl or heterocyclyl group is optionally substituted with one or more substituent groups selected from C 1-20 alkyl, C 5-20 aryl, halo, hydroxyl, ether, nitro, cyano, acyl, carboxy, ester, amido, amino, acylamido, ureido, acyloxy, thiol, thioether, sulfoxide, sulfonyl, thioamido, sulfonamido and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur;
R C1 and R C2 are both hydrogen; and
R 1 is selected from H and halo;
wherein the cancer is breast cancer or ovarian cancer; and
wherein the cancer comprises one or more cancer cells having a reduced or abrogated ability to repair DNA DSB by HR relative to normal cells.
2. The method of claim 1 , wherein the fused aromatic ring represented by A and B together is benzene.
3. The method of claim 1 , wherein R 1 is selected from H, Cl, and F.
4. The method of claim 1 , wherein R X is selected from H, C 1-20 alkyl, C 5-20 aryl, acyl, sulfonyl, amido, and thioamido groups, wherein the acyl, C 1-20 alkyl or C 5-20 aryl group is optionally substituted with one or more substituent groups selected from C 1-20 alkyl, C 5-20 aryl, halo, hydroxyl, ether, nitro, cyano, acyl, carboxy, ester, amido, amino, acylamido, ureido, acyloxy, thiol, thioether, sulfoxide, sulfonyl, thioamido, sulfonamido and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur.
5. The method of claim 1 , wherein the compound of formula (Ib) or an isomer or salt thereof, or a mixture of any thereof, is a compound of formula (II):
or an isomer or salt thereof, or a mixture of any thereof, wherein:
R C3 is selected from C 1-7 alkyl, C 5-20 aryl, and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur, wherein the C 1-7 alkyl, C 5-20 aryl or heterocyclyl group is optionally substituted with one or more substituent groups selected from C 1-20 alkyl, C 5-20 aryl, halo, hydroxyl, ether, nitro, cyano, acyl, carboxy, ester, amido, amino, acylamido, ureido, acyloxy, thiol, thioether, sulfoxide, sulfonyl, thioamido, sulfonamido and a heterocyclyl group having from 3 to 7 ring atoms, of which from 1 to 4 are selected from nitrogen, oxygen and sulfur.
6. The method of claim 1 , wherein the compound of formula (Ib) or an isomer or salt thereof, or a mixture of any thereof, is a compound of formula (III):
or an isomer or salt thereof, or a mixture of any thereof, wherein R is selected from:
7. The method of claim 1 , wherein the compound of formula (Ib) or an isomer or salt thereof, or a mixture of any thereof, is a compound of formula (IV),
or an isomer or salt thereof, or a mixture of any thereof.
8. The method of claim 1 , further comprising identifying the subject as having a cancer condition that is deficient in a HR dependent DNA DSB repair pathway.
9. The method of claim 1 , further comprising administering ionizing radiation, a chemotherapeutic agent, or a combination thereof to the subject.
10. The method of claim 1 , wherein the one or more cancer cells has a BRCA1 or BRCA2 deficient phenotype.
11. The method of claim 10 , wherein the one or more cancer cells are deficient in BRCA1 or BRCA2.
12. The method of claim 1 , wherein the subject is heterozygous for a mutation in a gene encoding a component of the HR dependent DNA DSB repair pathway.